CN107213197A - A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared - Google Patents
A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared Download PDFInfo
- Publication number
- CN107213197A CN107213197A CN201710484465.2A CN201710484465A CN107213197A CN 107213197 A CN107213197 A CN 107213197A CN 201710484465 A CN201710484465 A CN 201710484465A CN 107213197 A CN107213197 A CN 107213197A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- sage root
- red sage
- ligusticum wallichii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of Chinese medicine composition and the application in prevention or treatment hypertension is prepared with the red sage root and Rhizoma Chuanxiong extractum powder, the Chinese medicine composition is mainly 1-9 parts, 4-6 parts of Rhizoma Chuanxiong extractum powder is prepared from, the pharmaceutical composition antihypertensive effect well, stably, has no obvious toxic-side effects.
Description
Technical field
Prevent or treatment hypertension drug the invention belongs to the field of Chinese medicines, specifically a kind of Chinese medicine composition and its preparing
In application.
Background technology
According to statistics, the patient of whole world high blood pressure is up to as many as 600,000,000, and the aging with population, bad life
Custom, shortcoming of health education etc., cause Prevalence of Hypertension, complication rate to remain high, be cause a variety of hearts,
The key factor of cranial vascular disease, is also one of dead principal element of angiocardiopathy.Cause the cause of disease of hypertension except losing
Outside biography factor, diet structure is unreasonable, overfeeding sodium salt and the excessive saturated fatty acid of intake can cause subcutaneous fat to increase, and presses
Compel blood vessel, blood fat increases, vascular wall constriction, causes blood flow to be obstructed.The medicine of current clinical treatment hypertension has calcium ion
Antagonist nifedipine, angiotensin converting enzyme inhibitor captopril, diuretic hypotensive agent Hydrochioro etc., but these changes
Though it is very fast to learn medicine curative effect, dizziness, fash, nausea etc. occurs in long-term taking, or even low blood pressure, palpitaition, Dou Xingxin occurs
The dynamic adverse reaction such as overrun.On the contrary, the Chinese medicine composition relative components of the present invention understand, effect relaxes steadily, and can adjust machine
Body function, adverse reaction and drug dependence are few, improve the adaptability of patient.
The red sage root is the labiate red sage root Salvia miltiorrhiza Bge. dry root and rhizome, is in commonly using
Medicine, the red sage root has promoting blood circulation, and relieving restlessness that clears away heart-fire is inducing meastruation to relieve menalgia, the effect of cool blood to disappear carbuncle.For chest impediment and cardialgia, gastral cavity abdomen hypochondriac pain, the heart
Tired egersis etc..The clinical studies show such as Fang Kuaifa red sage root steadily has a significant effect (square to the ambulatory blood pressure of hyperpietic
Fast hair, Yang Youxiang, Wang Ningsheng wait the reds sage root to research [J] Chinese and Western of hypertension patients ambulatory blood pressure and hazards
Doctor combines cardiovascular and cerebrovascular diseases magazine, 2004,2 (3):133-135.).
Ligusticum wallichii is samphire Ligusticum wallichii Ligusticum chuanxiong Hort. dry rhizome, is conventional Chinese medicine,
The effect of Ligusticum wallichii has blood-activating and qi-promoting, wind-expelling pain-stopping, for diseases such as stagnation of blood stasis, head wind headache, arthralgia pain due to rheumatism.
Perhexiline injection is made up of the red sage root and Ligusticum wallichii, with functions such as promoting blood circulation and removing blood stasis, freeing vessels and nourishing hearts, for the coronary heart disease heart
Angina [the Sanitation Ministry medicine standard, the 17th page 174].But it is that drug regimen is being prevented and treated using the red sage root and Rhizoma Chuanxiong extractum powder
Application in terms of high blood pressure disease has no report.
The content of the invention
Match somebody with somebody the technical problem to be solved in the present invention is to provide a kind of Chinese medicine of the small antihypertensive of evident in efficacy, toxic side effect
Side.
Adopted the following technical scheme that to solve the above-mentioned technical problem present invention：
A kind of Chinese medicine composition, it is made up of the raw material of following parts by weight：1-9 parts of the red sage root, 4-6 parts of Ligusticum wallichii.
Preferably, the Chinese medicine composition, it is made up of the raw material of following parts by weight：3-7 parts of the red sage root, 5 parts of Ligusticum wallichii.
First extract powder is made in the red sage root and Ligusticum wallichii by the Chinese medicine composition together, is then constituted with pharmaceutically acceptable carrier
Clinical acceptable oral preparations, including tablet, capsule, pulvis, pill.
Wherein in the extract powder of the red sage root and Ligusticum wallichii the purity of tanshin polyphenolic acid B be more than or equal to 4%, the purity of forulic acid be more than or
Equal to 0.07%.
The Chinese medicine preparation of antihypertensive of the present invention is made up of Radix Salviae Miltiorrhizae extractum powder and Rhizoma Chuanxiong extractum powder, and composition is simple, and pharmacology is real
Checking is bright, and the Chinese medicine composition has blood pressure lowering effect, and effect relaxes steadily, evident in efficacy.Antihypertensive effect of the present invention is good,
It is stable, obvious toxic-side effects are had no, oral Pharmaceutical dosage forms technological operation are made into easy.
Brief description of the drawings
Fig. 1 is therapeutic action of the red sage root of the present invention with szechuan lovage rhizome composition to spontaneous hypertensive rat (SHR) morbidity early stage
As a result；
Note：A:The red sage root and intervention effect of the szechuan lovage rhizome composition to SHR rats morbidity early stage SBP；B：The red sage root is combined with Ligusticum wallichii
Intervention effect of the thing to SHR rats morbidity early stage DBP；C:Intervention of the red sage root with szechuan lovage rhizome composition to SHR rats morbidity early stage MBP
Effect.Compared with Normal group#P<0.05,##P<0.01；Compared with model control group*P<0.05,**P<0.01。
Fig. 2 is the red sage root of the present invention and therapeutic action result of the szechuan lovage rhizome composition to SHR rats；
Note：A:The red sage root and therapeutic action of the szechuan lovage rhizome composition to SHR rats SBP；B：The red sage root is big to SHR with szechuan lovage rhizome composition
Mouse DBP therapeutic action；C:The red sage root and therapeutic action of the szechuan lovage rhizome composition to SHR rats MBP.Compared with Normal group#P<
0.05,##P<0.01；Compared with model control group*P<0.05,**P<0.01。
Embodiment
Prepare embodiment 1
Take red sage root 178g and Ligusticum wallichii 889g to mix, prepare extract powder, add 600g microcrystalline celluloses, mix, directly
Pressed powder is connect, tablet is produced.
The preparation method of the wherein red sage root and Rhizoma Chuanxiong extractum powder is as follows：
The red sage root and Ligusticum wallichii are taken, is added water to cook respectively three times, first time amount of water is 8 times of amounts, is decocted 2 hours, second and third time
Amount of water is 6 times of amounts, is decocted 1.5 hours, collecting decoction, filtration, and it is 1.20~1.25 that filtrate decompression, which is concentrated into relative density,
The clear cream of (50 DEG C).Adding ethanol makes alcohol content up to 75%, stands overnight.Supernatant is taken, ethanol is recovered under reduced pressure, is concentrated into relative
Density is the clear cream of 1.25~1.35 (50 DEG C), through being dried to obtain extract powder.
Prepare embodiment 2
Take red sage root 889g and Ligusticum wallichii 889g to mix, prepare extract powder, add 600g microcrystalline celluloses, mix, directly
Pressed powder is connect, tablet is produced.
The preparation method of wherein Radix Salviae Miltiorrhizae extractum powder and Rhizoma Chuanxiong extractum powder is as follows：
The red sage root and Ligusticum wallichii are taken, is added water to cook respectively three times, first time amount of water is 8 times of amounts, is decocted 2 hours, second and third time
Amount of water is 6 times of amounts, is decocted 1.5 hours, collecting decoction, filtration, and it is 1.20~1.25 that filtrate decompression, which is concentrated into relative density,
The clear cream of (50 DEG C).Adding ethanol makes alcohol content up to 75%, stands overnight.Supernatant is taken, ethanol is recovered under reduced pressure, is concentrated into relative
Density is the clear cream of 1.25~1.35 (50 DEG C), through being dried to obtain extract powder.
Prepare embodiment 3
Take red sage root 1600g and Ligusticum wallichii 889g to mix, prepare extract powder, add 600g microcrystalline celluloses, mix, directly
Pressed powder is connect, tablet is produced.
The preparation method of wherein Radix Salviae Miltiorrhizae extractum powder and Rhizoma Chuanxiong extractum powder is as follows：
The red sage root and Ligusticum wallichii are taken, is added water to cook respectively three times, first time amount of water is 8 times of amounts, is decocted 2 hours, second and third time
Amount of water is 6 times of amounts, is decocted 1.5 hours, collecting decoction, filtration, and it is 1.20~1.25 that filtrate decompression, which is concentrated into relative density,
The clear cream of (50 DEG C).Adding ethanol makes alcohol content up to 75%, stands overnight.Supernatant is taken, ethanol is recovered under reduced pressure, is concentrated into relative
Density is the clear cream of 1.25~1.35 (50 DEG C), through being dried to obtain extract powder.
Experimental example 1：The red sage root and Ligusticum wallichii Chinese medicine composition are to high fat diet induced hypertension model Tibet Mini-Pigs blood pressure
Influence,
(1) experimental animal：Regular grade Tibet Mini-Pigs, male, 18,10~15kg of body weight is moved by Nanfang Medical Univ
The offer of thing experimental study center [SCXK (Guangdong) 201 --- --- ---], and raise real in Zhejiang University of Traditional Chinese Medicine animal
Test research center regular grade miniature pig laboratory [SYXK (Zhejiang) 2015-0184].
(2) modeling and administration
After all Tibet Mini-Pigs are raised 4-5 weeks through adaptability, vena cava anterior hematometry hepatic and renal function, blood fat, blood are taken
After the indexs such as sugar, blood routine are without exception, miniature pig is randomly divided into Normal group 6, basal feed is fed；High fat diet
Group 12, wherein high fat diet group carry out high lipid food feeding induction Tibet Mini-Pigs and induce hypertension model, and high lipid food is matched somebody with somebody
Side is 1.5% cholesterol, 15% grease, 10% yolk powder, 0.5% salt, 73% basal feed.After high fat diet 8 weeks, by height
Fat diet group is uniformly divided into two groups, i.e. high fat diet group and high fat diet+Chinese medicine composition intervention group by blood pressure level, wherein high
Fat diet+Chinese medicine composition intervention group successive administration 8 weeks, orally gives 81mg/kg Chinese medicine composition daily.Every 4 weeks of period
Determine the blood pressure of miniature pig.
(3) blood pressure measuring method
Under drying, ventilation, quiet environment, by each group miniature pig Baoding in stablizing 15min in canvas Shelf for keeing, then
Based on the noninvasive physiological signal telemetry system of the big animals of EMKA, miniature pig blood pressure is detected using afterbody office cuff, 10min is continuously measured
And recording blood pressure curve, with the systolic pressure (SBP) of ECG-Auto software analysis miniature pigs, diastolic pressure (DBP), mean arterial pressure
(MBP)。
(4) data processing
Using the statistical softwares of SPSS 22.0 handle, data result withRepresent, mean, which compares, between group uses single factor test
Variance analysis, is compared examined using L-S-D two-by-two, P<0.05 represents statistically significant.
(5) experimental result
From table 1-3 results, after high fat diet is induced 8 weeks, high fat diet group miniature pig systolic pressure, diastolic pressure and average
Angiosthenia is obviously higher than Normal group (P<0.05,P<0.01)；And give Chinese medicine composition 4 weeks and after 8 weeks, high fat diet
Systolic pressure, diastolic pressure and the mean arterial pressure of+Chinese medicine composition intervention group miniature pig are significantly lower than high fat diet group (P<
0.05, P<0.01).
The Chinese medicine composition of table 1 to high fat diet induced hypertension miniature pig systolic pressure (SBP) influence (MmHg, n
=6)
Note：With Normal group ratio,ΔP<0.05,ΔΔP<0.01；Compared with high fat diet group, * P<0.05,**P<0.01.
The Chinese medicine composition of table 2 to high fat diet induced hypertension miniature pig diastolic pressure (DBP) influence (MmHg, n
=6)
Note：With Normal group ratio,ΔP<0.05,ΔΔP<0.01；Compared with high fat diet group, * P<0.05,**P<0.01.
The Chinese medicine composition of table 3 to high fat diet induced hypertension miniature pig mean arterial pressure (MBP) influence (
MmHg, n=6)
Note：With Normal group ratio,ΔP<0.05,ΔΔP<0.01；Compared with high fat diet group, * P<0.05,**P<0.01.
Experimental example 2：Therapeutic action of the red sage root with szechuan lovage rhizome composition to spontaneous hypertensive rat (SHR) morbidity early stage
Material：The red sage root and szechuan lovage rhizome composition extract powder, valsartan capsule, aqua sterilisa
Experimental animal：SPF grades of male SHR rats and male SD rat, are 7~8 week old, blood pressure (SBP：190.30±
11.33, DBP：142.14±7.52,MBP:158.32±8.85).
1. experimental method
1.1. animal packet and administration
18 7~8 week old SHR male rats are taken, 6 SD male rats with week old are separately taken, raised by 3/cage.Adapt to
Property raise 1 week after, weigh and by noninvasive arteria caudalis detect blood pressure, SHR rats are divided into uniform 3 by pressure value stratified random
Group, i.e. model control group (aqua sterilisa 10mL/kg), composition group (red sage root and szechuan lovage rhizome composition extract powder 200mg/kg) and the positive
Control group (Valsartan 30mg/kg), every group 6, SD rats are used as Normal group (aqua sterilisa 10mL/kg).
1.2. ordinary circumstance is observed
During experiment, daily observation rat fur, diet, drinking-water situation, rat excreta color and metamorphosis, and
Movable mental condition etc..
1.3. blood pressure determination
When before administration with being administered 1 week, 3 weeks and 5 weeks, noninvasive arteria caudalis office cuff is used to detect blood pressure.Gently by animal
It is put into fixator, animal training is needed for several times before surveying for the first time, it is accustomed to fixing device, reduction stress.Simultaneously using heating
Device so that temperature is at 28~33 DEG C, and such animal afterbody circulation is good, and pulse is easily detected, but temperature is too high, is occurred
Animal breath accelerates and had the fidgets.Pulse transducer has been debugged to cause it is observed that at least after 10s normal pulses ripple waveform then
It is measured, tail sleeve inflating pressure is given using aerating device.Until pulse wave is decreased to disappear, stop inflating and deflating, pressure
Decline, pulse wave reappears, so far completes once to determine.Animal recovers to carry out second of measure after 2min, repeats 4~5 times
Data are counted.Whole determination of the environment requires quiet noiseless, in order to avoid cause Animal stress.
1.4. statistical analysis
Data are represented with (mean+SD), and Student T inspections, P are carried out using SPSS22.0 softwares<0.05 table
It is shown with significant difference.
2. experimental result
Compared with Normal group, model control group before administration (0 week), administration 1 week, 3 weeks and 5 weeks when, systolic pressure
(SBP), diastolic pressure (DBP) and mean arterial pressure (MBP) significantly rise (P<0.01).Compared with model control group, composition
Group is when being administered 3 weeks and 5 weeks, and SBP, DBP, MBP significantly reduce (P<0.05, P<0.01).See Fig. 1.
Experimental example 3：The red sage root and therapeutic action of the szechuan lovage rhizome composition to SHR rats
Material：The red sage root and szechuan lovage rhizome composition extract powder, valsartan capsule, aqua sterilisa
Experimental animal：SPF grades of male SHR rats and male SD rat, 10~12 week old.
1. experimental method
1.1. animal packet and administration
18 10~12 week old SHR male rats are taken, 6 SD male rats with week old are separately taken, raised by 3/cage.It is suitable
After answering property is raised 3 days, weigh, every other day noninvasive arteria caudalis measuring blood pressure, it is continuous to detect 3 times, confirm that each rat is height
After blood pressure rats model, animal stratified random is divided into uniform 3 groups, i.e. model control group according to 3 average blood pressures and body weight
(aqua sterilisa 10mL/kg), composition group (red sage root and szechuan lovage rhizome composition extract powder 300mg/kg) and positive controls (Valsartan
30mg/kg), every group 6, SD rats are used as Normal group (aqua sterilisa 10mL/kg).
1.2. ordinary circumstance is observed
During experiment, daily observation rat fur, diet, drinking-water situation, rat excreta color and metamorphosis, and
Movable mental condition etc..
1.3. blood pressure determination
Blood pressure is detected when before administration with being administered 2 weeks and 4 weeks, method is with example 1.
1.4. statistical analysis
Data are represented with (mean+SD), and Student T inspections, P are carried out using SPSS22.0 softwares<0.05 table
It is shown with significant difference.
2. experimental result
Compared with Normal group, model control group before administration (0 week) with administration after 2 weeks and 4 weeks, systolic pressure (SBP),
Diastolic pressure (DBP) and mean arterial pressure (MBP) significantly rise (P<0.01).Compared with model control group, composition group to
Medicine 2,4 weeks when, SBP, DBP, MBP significantly reduce (P<0.05, P<0.01).See Fig. 2.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Any modifications, equivalent substitutions and improvements made within principle etc., are all contained within protection scope of the present invention.
Claims (5)
1. a kind of Chinese medicine composition, it is characterised in that it is made up of the raw material of following parts by weight：1-9 parts of the red sage root, Ligusticum wallichii 4-6
Part.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that it is made up of the raw material of following parts by weight：The red sage root 3-7
Part, 5 parts of Ligusticum wallichii.
3. Chinese medicine composition as claimed in claim 1 or 2, it is characterised in that extract powder is first made in the red sage root and Ligusticum wallichii together,
Then clinical acceptable oral preparations, including tablet, capsule, pulvis, pill are constituted with pharmaceutically acceptable carrier.
4. Chinese medicine composition as claimed in claim 3, it is characterised in that tanshin polyphenolic acid B in the extract powder of the red sage root and Ligusticum wallichii
Purity is more than or equal to 4%, and the purity of forulic acid is more than or equal to 0.07%.
5. application of the Chinese medicine composition as claimed in claim 1 or 2 in prevention or treatment hypertension drug is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710484465.2A CN107213197A (en) | 2017-06-23 | 2017-06-23 | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710484465.2A CN107213197A (en) | 2017-06-23 | 2017-06-23 | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107213197A true CN107213197A (en) | 2017-09-29 |
Family
ID=59950317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710484465.2A Pending CN107213197A (en) | 2017-06-23 | 2017-06-23 | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213197A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578496A (en) * | 2018-05-31 | 2018-09-28 | 海宁卫生学校 | A kind of Chinese medicine for treating hypertension |
| CN111419899A (en) * | 2020-04-20 | 2020-07-17 | 浙江众博堂生物科技有限公司 | Cyclocarya paliurus compound medicinal liquor and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368352A (en) * | 2001-02-05 | 2002-09-11 | 杨孟君 | Nano medicine 'Guanxinning' and its preparing process |
| CN1813891A (en) * | 2005-11-28 | 2006-08-09 | 孟繁浩 | Perhexiline high-dose injection and its preparing method |
-
2017
- 2017-06-23 CN CN201710484465.2A patent/CN107213197A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368352A (en) * | 2001-02-05 | 2002-09-11 | 杨孟君 | Nano medicine 'Guanxinning' and its preparing process |
| CN1813891A (en) * | 2005-11-28 | 2006-08-09 | 孟繁浩 | Perhexiline high-dose injection and its preparing method |
Non-Patent Citations (1)
| Title |
|---|
| 郭小瑞等: "RP-HPLC法同时测定冠心宁冻干粉针剂中丹酚酸B和阿魏酸的含量", 《药物分析杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578496A (en) * | 2018-05-31 | 2018-09-28 | 海宁卫生学校 | A kind of Chinese medicine for treating hypertension |
| CN111419899A (en) * | 2020-04-20 | 2020-07-17 | 浙江众博堂生物科技有限公司 | Cyclocarya paliurus compound medicinal liquor and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN104645091A (en) | Capsule for treating hypertension | |
| US20150065452A1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN104027529A (en) | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof | |
| CN106176773A (en) | Berberine hydrochloride and stachyose composition compositions and application | |
| CN107213197A (en) | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN106474356A (en) | A kind of medicine of logical stalkization bolt and preparation method thereof | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN109758497B (en) | Traditional Chinese medicine composition and medicine for chronic heart failure and preparation method and application thereof | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| Gao et al. | Radix astragali and orthostatic response: a double-masked crossover study | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170929 |